Coherus Oncology (CHRS) Other financing activities (2014 - 2026)

Coherus Oncology (CHRS) has 13 years of Other financing activities data on file, last reported at $52000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $52000.0; the trailing twelve-month figure through Mar 2026 stood at $217000.0 (changed N/A YoY), and the FY2025 full-year result was $353000.0, up 720.93% from the prior year.
• Other financing activities retreated to $52000.0 in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $3.2 million in Q4 2022 to a low of -$2.5 million in Q3 2022.
• A 5-year average of $251846.2 and a median of $52000.0 in 2026 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities jumped 147.31% in 2022 and sank 14785.71% in 2025, its largest moves.
• Tracing CHRS's Other financing activities over 5 years: stood at $3.2 million in 2022, then tumbled by 120.21% to -$643000.0 in 2023, then surged by 98.91% to -$7000.0 in 2024, then soared by 17342.86% to $1.2 million in 2025, then tumbled by 95.69% to $52000.0 in 2026.
• Business Quant data shows CHRS's Other financing activities at $52000.0 in Q1 2026, $1.2 million in Q4 2025, and -$1.0 million in Q3 2025.